|
|
|
|
|
| Castro,T.B.M.; Hallack Neto,A.E.; Atalla,A.; Ribeiro,L.C.. |
| In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study. Data were collected through interviews, clinical observation, and from hospital records. A total of 59 patients were included. There was a predominance of females, 36 (61%) vs 23 (39%) males, and of whites, 49 (83.1%) vs 10 (16.9%) blacks. Age ranged from 40 to 94 years, with a median of 65 years (SD=11.6). Regarding staging at diagnosis, 27 (45.7%) patients were in stage III-A, with 12 (20.3%) patients having serum creatinine ≥2 mg/dL. The main adverse effects in the bortezomib treatment group (n=40) were: neutropenia (42.5%), diarrhea (47.5%), and peripheral neuropathy in 60% of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Multiple myeloma; Side effects; Bortezomib; Thalidomide. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000600705 |
| |
|
|
| Hallack Neto,A.E.; Pereira,J.; Beitler,B.; Chamone,D.A.F.; Llacer,P.D.; Dulley,F.L.; Macedo,M.C.M.A.; Chaoubah,A.. |
| Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Diffuse large B-cell lymphoma; CHOP lymphoma treatment; ProMACE-CytaBOM treatment. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007 |
| |
|
|
|
